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Bone mass and turnover are maintained by the coordinated balance between bone formation by osteoblasts and bone
resorption by osteoclasts, under regulation of many systemic and local factors. Phosphoinositide-dependent serine-threonine
protein kinase Akt is one of the key players in the signaling of potent bone anabolic factors. This study initially showed that the
disruption of Akt1, a major Akt in osteoblasts and osteoclasts, in mice led to low-turnover osteopenia through dysfunctions of
both cells. Ex vivo cell culture analyses revealed that the osteoblast dysfunction was traced to the increased susceptibility to
the mitochondria-dependent apoptosis and the decreased transcriptional activity of runt-related transcription factor 2 (Runx2),
a master regulator of osteoblast differentiation. Notably, our findings revealed a novel role of Akt1/forkhead box class O
(FoxO) 3a/Bim axis in the apoptosis of osteoblasts: Akt1 phosphorylates the transcription factor FoxO3a to prevent its nuclear
localization, leading to impaired transactivation of its target gene Bim which was also shown to be a potent proapoptotic
molecule in osteoblasts. The osteoclast dysfunction was attributed to the cell autonomous defects of differentiation and
survival in osteoclasts and the decreased expression of receptor activator of nuclear factor-kB ligand (RANKL), a major
determinant of osteoclastogenesis, in osteoblasts. Akt1 was established as a crucial regulator of osteoblasts and osteoclasts by
promoting their differentiation and survival to maintain bone mass and turnover. The molecular network found in this study
will provide a basis for rational therapeutic targets for bone disorders.
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INTRODUCTION
Bone is continually remodeled according to physiological circum-
stances through bone formation by osteoblasts and bone
resorption by osteoclasts, and bone mass and turnover are
maintained by their coordinated balance in healthy adults. Many
systemic and local factors are involved in the regulation [1,2],
among which insulin, insulin-like growth factor-I (IGF-I), bone
morphogenetic factors (BMPs), and Wnt proteins are potent bone
anabolic factors [3–6]. A serine-threonine kinase Akt, also called
protein kinase B (PKB), is known as a potent signal transducer of
these bone anabolic factors [7–9].
There are three Akt family members, Akt1/PKBa, Akt2/PKBb
and Akt3/PKBc. Akt1 and Akt2, but not Akt3, are reported to be
ubiquitously and similarly expressed in various tissues, although
Akt2 is expressed more predominantly in insulin target tissues such
as fat, liver and muscle [9,10]. Accordingly, Akt1-/- mice and
Akt2-/- mice show similar phenotypes including dwarfism, except
that only the latter exhibit severe diabetes [10–13]. Although
phenotype of mice lacking single Akt isoform is relatively mild
possibly due to functional redundancy of the remaining isoforms,
double-knockout of Akt1 and Akt2 in mice causes severely
impaired bone development and death shortly after birth [14].
The abnormalities of these knockout mice certainly imply a crucial
commitment of Akt signals to bone metabolism, yet it has
remained unknown whether or not these were due to the cell
autonomous effects of the Akt deficiency on bone cells. To
elucidate the physiological role of the Akt signaling in the
regulation of bone formation and resorption, the present study
initially analyzed the bones of mice lacking Akt1, a major Akt
isoform in bone, and found that the deficiency caused osteopenia
with a low turnover state. We further investigated the underlying
cellular and molecular mechanisms in osteoblasts and osteoclasts.
RESULTS
Akt1 is a major isoform in bone cells
We initially confirmed that the total Akt (Akt1–3) was phosphor-
ylated by osteogenic factors IGF-I and BMP-2 in cultured
osteoblasts, and by a bone resorptive macrophage colony-
stimulating factor (M-CSF) in osteoclast-progenitor bone marrow
macrophages (BMM) and mature osteoclasts (Supp. Fig S1A).
Among the three Akt isoforms, Akt1 and Akt2 were highly
expressed in these bone cells (Supp. Fig S1B).
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Akt1 deficiency causes decreased bone mass and
formation
To investigate the physiological role of the Akt signaling in bone,
we examined the bone phenotype of Akt1 deficient (Akt1-/-) mice,
because Akt1; Akt2 double-knockout mice die shortly after birth
[14]. Akt1-/- mice were healthy and fertile without abnormality in
major organs or skeletal patterning, but were smaller in size
compared to the wild-type (WT) littermates (Supp. Fig S2) as
previously reported [11]. Radiological analyses of long bones in 8
week-old mice using plain X-ray, bone mineral density (BMD)
analysis (Fig 1A), three dimensional (3D) CT (Fig 1B), and
peripheral quantitative CT (pQCT) (Fig 1C) revealed decreases in
both trabecular and cortical bones as a result of the Akt1
deficiency. Although the growth plate was not affected (Fig 1D),
bone formation parameters (MAR&BFR) of the trabecular bone
were decreased (Fig 1E), indicating that osteopenia in the Akt1-/-
mice was at least partly due to the impairment of osteoblastic bone
formation. This defect was accompanied by a decrease in the
number of osteoblasts shown by the percentage of bone surface
covered by cuboidal osteoblasts (Ob.S/BS) and an increase in that
of apoptotic osteoblasts shown by terminal deoxynucleotidyl
transferase mediated dUTP nick-end-labeling (TUNEL)-positive
cells (Fig 1E).
Akt1 deficiency enhances susceptibility to apoptosis
of osteoblasts via FoxO3a
To learn the mechanism of impaired bone formation, we
compared ex vivo functions of osteoblasts isolated from WT and
Akt1-/- littermates. We first confirmed that both phosphorylated
and unphosphorylated Akt proteins were considerably decreased
in cultured Akt1-/- osteoblasts without compensatory increase of
Akt2 protein, indicating a substantial suppression of the total Akt
signaling by depletion of an isoform Akt1 in osteoblasts (Fig 2A).
Although cell proliferation was not affected (Fig 2B), cell survival
after serum deprivation was decreased by the Akt1 deficiency
(Fig 2C). This decrease was confirmed to be due to the enhanced
susceptibility to apoptosis of osteoblasts by TUNEL staining
(Fig 2D). Caspase-3 activity and the cleaved active form was
enhanced in Akt1-/- osteoblasts, which was restored by adenoviral
introduction of a constitutively active form of Akt1 (Akt1CA) or
Bcl-xL, a specific inhibitor of mitochondria-dependent apoptosis
[15] (Fig 2E). Hence, Akt1 deficiency in osteoblasts is not likely to
affect the proliferation, but suppresses the survival through an
enhanced susceptibility to mitochondria-dependent apoptosis.
Among apoptosis-related molecules that have been reported to
be possible substrates of Akt [9,16], transcription factors FoxO3a
and FoxO1, and a proapoptotic molecule Bad were expressed in
primary osteoblasts and osteoblastic cell line MC3T3-E1 (Fig 2F).
Since phosphorylation of FoxO proteins is known to result in their
nuclear exclusion in other types of cells [16], we confirmed the
nuclear entry of FoxO3a after serum deprivation in MC3T3-E1
cells (Supp. Fig S3). The nuclear localization of FoxO3a was more
enhanced in Akt1-/- osteoblasts than in WT after serum
deprivation (Fig 2G). This correlated with the decrease of the
upper band and the increase of the lower band in the cytoplasmic
fraction of the immunoblotting, which were proved to be
phosphorylated and unphosphorylated FoxO3a, respectively, since
the upper one was enhanced by FBS and eliminated by lambda
protein phosphatase (Fig 2H). Meanwhile, Akt1 overexpression by
Akt1CA transfection in osteoblasts stimulated the cytoplasmic
FoxO3a phosphorylation and inhibited the nuclear entry (Fig 2I).
Contrarily, subcellular localization of FoxO1 was not affected by
the Akt1 deficiency (Fig 2G), nor was phosphorylated Bad protein
detected in osteoblasts, probably due to its low level (data not
shown). Finally, the decreased survival rate and the increased
caspase-3 activity of Akt1-/- osteoblasts after serum deprivation
were restored by introduction of a dominant-negative form of
FoxO3a (FoxO3aDN) (Fig 2J, K).
The lines of results indicate that a transcription factor FixO3a is
a phosphorylation target of Akt1 in the anti-apoptotic action on
osteoblasts, so that the Akt1 deficiency attenuates FoxO3a
phosphorylation and nuclear exclusion, which leads to the
enhanced transcriptional activity somehow causing apoptosis.
Akt1 suppresses osteoblast apoptosis through
inhibition of FoxO3a and Bim
We next sought to identify the transcriptional target of FoxO3a
that lies downstream of the Akt1 anti-apoptotic signaling in
osteoblasts. Among the candidate molecules Fas ligand, Bim, and
Bcl-xL that were reported previously in other tissues [17], only Bim
mRNA level was increased after serum deprivation in osteoblasts
(Fig 3A). Bim protein level was also increased, followed by the
induction of cleaved caspase-3, while none of the major regulators
of mitochondria-dependent apoptosis: proapoptotic Bax, anti-
apoptotic Bcl-2 and Bcl-xL [15], was affected by serum deprivation
(Fig 3B). The cleaved caspase-3 induction was mediated by Bim,
since it was suppressed by silencing of Bim through RNA
interference (Fig 3C). Actinomycin D, an inhibitor of RNA
transcripion, canceled the Bim increase after serum deprivation,
indicating that this is a transcriptional induction (Supp. Fig S4A,
B). The Bim promoter activity was actually enhanced by FoxOs,
among which FoxO3a exhibited the strongest transactivity
(Fig 3D). Endogenous Bim expression was confirmed to be
enhanced by FoxO3a overexpression and attenuated by the
suppression (Fig 3E, F). These results indicate that Bim is
a transcriptional target of FoxO3a in osteoblasts.
We then looked at the involvement of Akt1 in the FoxO3a and
Bim interaction in osteoblasts. Gain-of-function of Akt1 by Akt1CA
transfection abrogated the stimulation of the Bim promoter
activity by FoxO3a (Fig 3G). The induction of endogenous Bim
after serum deprivation was also suppressed by Akt1CA (Fig 3H) as
well as by insulin or IGF-I, potent activators of the Akt signaling
(Supp. Fig S4C). Finally, the Bim expression in Akt1-/- osteoblasts
was higher than that in WT osteoblasts, which was restored by the
FoxO3aDN transfection (Fig 3I).
Taken together, we conclude that Akt1 phosphorylates FoxO3a
to prevent it from translocating into nucleus, which leads to
suppression of Bim transactivation and osteoblast apoptosis.
Akt1 deficiency impairs Runx2-dependent
differentiation and function of osteoblasts
Since the in vivo histomorphometric analysis of the Alt1-/- bone
(Fig 1E) showed not only a decrease in osteoblast number, but also
a decrease in the ability of an individual osteoblast to form bone
(MAR), we performed ex vivo analyses of the effects of Akt1
deficiency on osteoblast differentiation and function, in addition to
their proliferation and apoptosis. The differentiation determined
by alkaline phosphatase (ALP) activity was impaired in Akt1-/-
osteoblasts in the control and stimulated cultures by insulin or
IGF-I, but not by BMP-2 (Fig 4A). Differentiation markers type I
collagen, ALP, bone sialoprotein, osteocalcin, Runx2 and osterix
were also decreased by Akt1 deficiency in osteoblasts (Fig 4B). This
was a cell autonomous function of Akt1 since the impaired
differentiation and matrix synthesis shown by ALP and Alizarin
red stainings in the Akt1-/- osteoblast culture were restored by
introduction of Akt1CA (Fig 4C). Interestingly, the Akt1CA
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Figure 1. Bone mass and formation are decreased in Akt1-/- mice. (A) Plain X-ray images of femur and tibia in WT and Akt1-/- male littermates at
8 weeks of age. The BMD of the entire femurs and tibias measured by DXA is shown in the graphs below. Data are expressed as means (bars)6SEM
(error bars) for 5 WT and 3 Akt1-/- littermates. **P,0.01 vs. WT. (B) Three-dimensional CT images of distal femurs. (C) pQCT images of the distal
metaphysis and the mid-diaphysis of the femurs. The color gradient indicating BMD is shown in the right bar. The trabecular content and density at
the metaphysis, and the cortical thickness and density at the diaphysis are shown in the graphs below. Data are expressed as means (bars)6SEM
(error bars) for 4 mice/group. *P,0.05 vs. WT. (D) Toluidine blue staining of the proximal tibias. Inset boxes indicate the regions of the bottom figures.
The growth plate heights were 94.762.9 and 95.863.8 mm for WT and Akt1-/-, respectively (mean6SEM of 4 mice/group). Bars, 200 mm (top)&30 mm
(bottom). (E) Bone formation parameters in histomorphometric analysis at the proximal tibias. MAR, mineral apposition rate; BFR/BS, bone formation
rate per bone surface; Ob.S/BS, osteoblast surface per bone surface; TUNEL(+), percentage of TUNEL-positive apoptotic osteoblasts. Data are
expressed as means (bars)6SEM (error bars) for 3–4 mice/group. *P,0.05, **P,0.01 vs. WT. The bottom figures show the representative calcein
double labelings; bars, 20 mm.
doi:10.1371/journal.pone.0001058.g001
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Figure 2. Akt1-/- osteoblasts are susceptibile to apoptosis via FoxO3a. (A) Time course of phosphorylated total Akt (P-Akt), total Akt (Akt), Akt1, Akt2,
and b-actin levels after IGF-I stimulation determined by Western blotting in cultured calvarial osteoblasts from WT and Akt1-/- mice. An asterisk indicates
a nonspecific band detected by an antibody to Akt1. (B) Cell proliferation determined by BrdU uptake into calvarial osteoblasts of two genotypes cultured
with and without insulin, IGF-I, or FGF-2. Data are expressed as means (bars)6SEM (error bars) for 6 wells/group. (C) Survival rate of WT and Akt1-/-
osteoblasts 48 h after serum deprivation in cultures with and without insulin or IGF-I. Data are expressed as means (bars)6SEM (error bars) for 6 wells/
group. *P,0.01 vs. WT. (D) The number of TUNEL-positive osteoblasts per field (66105 mm2) 24 h after serum deprivation in cultured calvarial osteoblasts.
Data are expressed as means (bars)6SEM (error bars) of 3 wells/group. *P,0.01 vs. WT. Bars, 100 mm. (E) Caspase-3 activity (top graph) and Western
blotting for cleaved caspase-3 and Bcl-xL (bottom) in WT and Akt1-/- osteoblasts adenovirally transfected with GFP, Akt1
CA, and Bcl-xL before and 6 h after
serum deprivation. Data are expressed as means (bars)6SEM (error bars) for 3 wells/group. *P,0.05 vs. WT. ADU: arbitrary densitometry unit. (F) FoxO3a,
FoxO1, FoxO4 and Bad expressions determined by RT-PCR in primary mouse calvarial osteoblasts (OB) and MC3T3-E1 cells (MC). (G) Time course of
FoxO3a, FoxO1, and b-actin levels by Western blotting after serum deprivation in the cytoplasmic (C) and nuclear (N) fractions of cultured WT and Akt1-/-
osteoblasts. Closed and open arrowheads indicate phosphorylated and unphosphorylated FoxO3a, respectively. (H) Western blotting for FoxO3a in the
cytoplasmic fraction of WT osteoblasts cultured with and without 10% FBS for 30 min. The lysates were treated with and without lambda protein
phosphatase (l-PPase). (I) Time course of FoxO3a and b-actin levels by Western blotting after serum deprivation in the cytoplasmic (C) and nuclear (N)
fractions of cultured osteoblasts adenovirally transfected with GPF or Akt1CA. (J) Survival rate of WT and Akt1-/- osteoblasts retrovirally transfected with
empty vector (EV) or FoxO3aDN 48 h after serum deprivation. Data are expressed as means (bars)6SEM (error bars) for 6 wells/group. *P,0.05 vs. Akt1-/-
with EV. (K) Caspase-3 activity of WT and Akt1-/- osteoblasts retrovirally transfected with EV or FoxO3aDN before and 6 h after serum deprivation. Data are
expressed as means (bars)6SEM (error bars) for 3 wells/group. *P,0.05 vs. Akt1-/- with EV. ADU: arbitrary densitometry unit.
doi:10.1371/journal.pone.0001058.g002
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Figure 3. Akt1 suppresses osteoblast apoptosis via inhibition of FoxO3a and Bim. (A) Time course of mRNA levels determined by real-time RT-PCR
of Bim, Fas ligand, and Bcl-xL after serum deprivation in cultured calvarial osteoblasts. Data are normalized to those of b-actin and are expressed as
means (symbols)6SEM (error bars) of the relative amount compared to time 0. (B) Time course of Bim, cleaved caspase-3, Bax, Bcl-2, Bcl-xL, and b-
actin levels determined by Western blotting after serum deprivation in cultured calvarial osteoblasts. (C) Western blotting for Bim, cleaved caspase-3,
and b-actin levels 6 h after serum deprivation in MC3T3-E1 cells retrovirally transfected with three kinds of Bim siRNA or the control GFP siRNA. (D)
Bim promoter activity determined by luciferase reporter assay in cultured MC3T3-E1 cells transfected with luciferase reporter constructs containing
a 2-Kb Bim 59-end flanking region. Plasmid vectors of the control GFP, FoxO1, FoxO3a, and FoxO4 were co-transfected in increasing amounts. Data
are expressed as means (bars)6SEM (error bars) of the fold change compared to GFP. (E, F) Bim mRNA level determined by real-time RT-PCR 3 h and
6 h after serum deprivation in MC3T3-E1 cells retrovirally transfected with FoxO3a (E), FoxO3aDN (F), or the respective EV. Data are normalized to
those of b-actin and are expressed as means (bars)6SEM (error bars) of the relative amount compared to time 0. (G) Bim promoter activity analysis in
MC3T3-E1 cells transfected with the control GFP, FoxO3a, and Akt1CA plasmid vectors in increasing amounts. Data are expressed as means
(bars)6SEM (error bars) of the fold change compared to GFP. (H) Time course of Bim, phosphorylated total Akt (P-Akt), total Akt (Akt), and b-actin
levels determined by Western blotting after serum deprivation in cultured calvarial osteoblasts adenovirally transfected with GPF or Akt1CA. (I) Bim
mRNA level determined by real-time RT-PCR 3 h and 6 h after serum deprivation in cultured WT and Akt1-/- osteoblasts retrovirally transfected with
EV or FoxO3aDN. Data are normalized to those of b-actin and are expressed as means (bars)6SEM (error bars) of the relative amount compared to
time 0. *P,0.05 vs. Akt1-/- with EV.
doi:10.1371/journal.pone.0001058.g003
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introduction failed to commit immature mesenchymal cell lines
C2C12 and C3H10T1/2 to osteoblastic lineage, although Runx2,
a master transcription factor for osteoblastic differentiation,
potently induced it (Supp. Fig S5).
These results suggest that Akt1 does not induce Runx2
expression but acts instead on differentiated osteoblasts that have
the potency to express Runx2. Hence, as a possible mechanism
underlying the osteogenic action of Akt1, we looked at its
modulation of Runx2 function. Akt1 overexpression by Akt1CA
introduction into Runx2 stable transfectants of MC3T3-E1 cells
enhanced the Runx2 activity on osteoblast differentiation and
function, and vice versa, while Akt1 silencing by the siRNA
introduction attenuated them (Fig 4D). Promoter activity of
osteocalcin, a representative transcriptional target of Runx2, in
Runx2-overexpressing MC3T3-E1 cells was also enhanced by
Akt1CA and suppressed by Akt1 siRNA (Fig 4E). Chromatin
immunoprecipitation (ChIP) showed that the complex of Runx2
and osteocalcin promoter seen in WT osteoblasts disappeared in
Akt1-/- osteoblasts (Fig 4F). Collectively, Akt1 is likely to enhance
the Runx2-dependent osteoblast differentiation and function
through enhancement of the DNA binding and the transcriptional
activity.
Akt1 deficiency impairs bone resorption via
dysfunctions of osteoclasts and osteoblasts
Finally, we investigated the role of Akt1 in bone resorption. The
number of osteoclasts determined by tartrate-resistant acid
phosphatase (TRAP) staining was reduced in the Akt1-/- bone
in vivo (Fig 5A), which was confirmed by decreased bone
Figure 4. Akt1 enhances Runx2-dependent osteoblast differentiation and function. (A) ALP activity of WT and Akt1-/- osteoblasts cultured with
and without insulin, IGF-I or BMP-2. Data are expressed as means (bars)6SEM (error bars) for 4 wells/group. *P,0.05 vs. WT. (B) mRNA levels of type I
collagen (COL1A1), ALP, bone sialoprotein (BSP), osteocalcin, Runx2, and osterix in WT and Akt1-/- osteoblasts determined by real-time RT-PCR. Data
are normalized to those of b-actin and are expressed as means (bars)6SEM (error bars) of the relative amount compared to WT culture. *P,0.01 vs.
WT. (C) ALP and Alizarin red stainings of WT and Akt1-/- osteoblasts with and without adenoviral transfection of GFP or Akt1CA. (D) ALP, Alizarin red,
and von Kossa stainings of MC3T3-E1 cells retrovirally transfected with Runx2 or the empty vector (EV). Runx2 transfectants were retrovirally co-
transfected with Akt1CA or the control EV, and Akt1 siRNA (siAkt1) or the control (siGFP). The graphs indicate mRNA levels of osteocalcin and Akt1
determined by real-time RT-PCR. Data are normalized to those of b-actin and are expressed as means (bars)6SEM (error bars) of the relative amount
compared to the control culture. (E) Osteocalcin promoter activity in retroviral Runx2 transfectants of MC3T3-E1 cells that were transfected with
luciferase reporter constructs containing a 1,050 bp osteocalcin 59-end flanking region. Plasmid vectors of Akt1CA, the negative control EV, and the
positive control Cbfb that is a representative co-activator of Runx2, as well as those of siAkt1 and the control EV were co-transfected. Data are
expressed as means (bars)6SEM (error bars) of the fold change compared to EV. (F) ChIP assay using cell lysates of WT and Akt1-/- osteoblasts
adenovirally transfected with GFP or Runx2. Purified DNA from with (IP) and without (input) immunoprecipitation by an antibody to Runx2 was
amplified by PCR using a primer set in the mouse osteocalcin promoter region (2471/267).
doi:10.1371/journal.pone.0001058.g004
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resorption parameters in the histomorphometric analysis (Fig 5B).
Osteoclastogenesis in the ex vivo co-culture was reduced when
either osteoblasts or bone marrow cells were derived from Akt1-/-
mice, and was additively reduced when both were from Akt1-/-
(Fig 5C). This indicates that Akt1 is necessary for osteoclast
precursors in a cell autonomous manner and for osteoblasts to
support osteoclast differentiation. Osteoclastogenesis in the culture of
osteoclast-progenitor BMM derived from Akt1-/- was suppressed
even in the presence of soluble receptor activator of nuclear factor
kB ligand (RANKL) and M-CSF (Fig 5D). Furthermore, the survival
of mature osteoclasts formed from Akt1-/- BMM was also impaired
(Fig 5E), confirming that the intrinsic Akt1 in osteoclastic cells is
necessary to maintain bone resorptive function. Contrarily, de-
creased expression of RANKL, but not osteoprotegerin or M-CSF,
in Akt1-/- osteoblasts (Fig 5F) explains the contribution of Akt1 in
osteoblasts to osteoclastic bone resorption.
Taken together, Akt1 deficiency may cause impairment of bone
resorption via the cell autonomous dysfunction in osteoclasts and
the cell non-autonomous inhibition of osteoclastogenesis due to
reduced RANKL expression in osteoblasts.
Figure 5. Akt1 deficiency impairs bone resorption via dysfunctions of osteoclasts and osteoblasts. (A) TRAP staining of proximal tibias of 8 week-
old WT and Akt1-/- mice. Bars, 100 mm. (B) Bone resorption parameters in histomorphometric analysis at the secondary spongiosa of the proximal
tibias. N.Oc/B. Pm, number of osteoclasts per 100 mm of bone perimeter; Oc.S/BS, osteoclast surface per bone surface; ES/BS, eroded surface per
bone surface. Data are expressed as means (bars)6SEM (error bars) for 3–4 mice/group. *P,0.05 vs. WT (+/+). (C) The number of TRAP-positive
multinucleated osteoclasts formed in the coculture of osteoblasts (OB) and bone marrow cells (BM) from WT or Akt1-/- littermates. Data are expressed
as means (bars)6SEM (error bars) for 4 wells/group. *P,0.05 vs. WT. Bars, 500 mm. (D) The number of TRAP-positive multinucleated osteoclasts
formed from BMM cultured in the presence of RANKL and M-CSF. Data are expressed as means (bars)6SEM (error bars) for 4 wells/group. *P,0.01 vs.
WT. Bars, 200 mm. (E) Time course of survival rate of mature osteoclasts after deprivation of RANKL and M-CSF. Mature osteoclasts were formed from
BMM in the presence of RANKL and M-CSF. Data are expressed as means (symbols)6SEM (error bars) for 4 wells/group. *P,0.05 vs. WT. (F) mRNA
levels of RANKL, osteoprotegerin, and M-CSF in cultured osteoblasts by real-time RT-PCR. Data are normalized to those of b-actin and are expressed
as means (bars)6SEM (error bars) of the relative amount compared to the WT culture. *P,0.01 vs. WT. (G) Schematic diagram of the mechanisms
underlying the Akt1 function to maintain bone mass and turnover. Akt1 suppresses the susceptibility to mitochondria-dependent apoptosis of
osteoblasts by inhibiting the FoxO3a nuclear entry and the Bim transactivation, and stimulates the differentiation and function by enhancing the
Runx2 transcriptional activity, resulting in increased bone formation. Akt1 also induces RANKL expression in osteoblasts to support osteoclast
differentiation, and shows cell-autonomous defects in osteoclasts to stimulate the differentiation and survival, resulting in increased bone resorption.
doi:10.1371/journal.pone.0001058.g005
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DISCUSSION
Physiological roles of Akt1 in bone
The present study initially analyzed the bones of mice lacking Akt1
and found that the deficiency caused osteopenia with a low
turnover state. Further in vivo and ex vivo analyses of osteoblasts
and osteoclasts revealed that the Akt1 deficiency caused impair-
ments of both bone formation and bone resorption via respective
cell autonomous mechanisms (Fig 5G). The imbalance between
formation and resorption, the underlying mechanism of which
remains to be clarified, may cause osteopenia with a low bone
turnover.
Akt1 in osteoblasts
Akt1 deficiency in osteoblasts caused three cell autonomous
abnormalities: increased susceptibility to apoptosis, suppressed
differentiation and function, and decreased RANKL expression to
support osteoclastogenesis. Most notably among them, the
enhanced apoptosis in Akt1-/- osteoblasts was shown to be
mitochondria-dependent via the FoxO3a nuclear entry and the
Bim transactivation. A recent report on mice with osteoblast-
specific deletion of phosphatase and tensin homolog (Pten)
demonstrated reduced osteoblast apoptosis and increased bone
mass by constitutive activation of Akt signaling, corresponding to
the present finding, although the downstream molecular mecha-
nism remained unclarified [18]. The candidates of substrates of
Akt1 included caspase-9, Bad, and FoxOs whose involvement in
mitochondria-dependent apoptosis had been established in other
cells [9]. Although caspase-9 functions as one of the most
important effectors in the apoptosis, the lack of a minimal
substrate consensus sequence for Akt [9] led us to exclude this
from the candidates. A proapoptotic molecule Bad was expressed
in osteoblasts, but the phosphorylation could not be detected.
FoxO proteins identified in mammals, FoxO1, FoxO3a and
FoxO4, constitute a newly characterized subfamily of the Fork-
head/winged helix group of transcription factors and play
a predominant role in mediating various functions of the PI3K/
Akt pathway [16,17]. Although disruption of the genes in mice has
revealed the necessities of FoxO1 in embryonic vessel formation
and FoxO3a in ovarian follicular development [19], their roles in
bone metabolism remained unknown. This study showed expres-
sions of FoxO1 and FoxO3a, but not FoxO4, in osteoblasts, and
functional involvement of FoxO3a in their survival as a phosphor-
ylation target of Akt1. Contrarily, the nuclear entry of FoxO1 after
serum deprivation was independent of Akt1 (Fig 2G), implicating
that different isoforms of Akt may have specific preference to
FoxO proteins as the substrates. In fact, similarly to Akt2, FoxO1
is expressed predominantly in insulin target tissues and regulates
their insulin resistance [16].
Bim, Bcl-2-interacting mediator of cell death, was shown to be
a transcriptional target of FoxO3a that lies downstream of the
Akt1 anti-apoptotic signaling in osteoblasts. Proapoptotic activity
of Bim is regulated both transcriptionally and post-transcription-
ally [20], and the transcriptional induction is known to be
mediated by FoxOs under the apoptotic stimulation in other cells
[17,21–23]. Studies on knockout mice have revealed that Bim is
essential for apoptosis of lymphocytes, myeloid cells, neurons, and
osteoclasts [24,25]. Regarding osteoblast apoptosis, the involve-
ment of Bcl-2 family proteins such as Bax and Bcl-2 has been
reported [7,26]. Because the changes in protein levels of these
molecules are crucial for osteoblast apoptosis, these changes seem
to be independent of the Bim regulation.
Suppressed differentiation and function in Akt1-/- osteoblasts
was shown to be mediated at least partly by modulating the Runx2
activity. The present results using Akt1-null materials confirmed
a previous report by Fujita et al. that gain- and loss-of-functions of
PI3K/Akt signaling regulate the DNA binding and transactivity of
Runx2 in cultures of osteoblastic cells [27]. Since Runx2 does not
have a consensus sequence for Akt phosphorylation, Akt is not
likely to phosphorylate Runx2 directly, but may regulate the
activity or stability of co-activators or co-repressors of Runx2.
However, the fact that Akt1-/- mice did not exhibit cleidocranial
dysplasia (Supp. Fig S2B), the characteristic phenotype of
Runx2+/2 mice, indicates that Akt1 is not a crucial regulator
of the Runx2-dependent bone formation in vivo.
Akt1 in osteoclasts
Besides the defects in osteoblasts, the deficiency of Akt1 in
osteoclasts caused impairment of bone resorption via the cell
autonomous dysfunction. To date, the role of Akt signaling in
osteoclasts has been controversial. RANKL and M-CSF have been
reported to promote the osteoclast survival in part by activating
the Akt pathway [28,29]. Contrarily, Akt is shown to be
dispensable for the survival by knockdown experiment using
Akt1/Akt2 siRNA, but is necessary for the proliferation and
differentiation [30]. Our results using ex vivo cultures of isolated
Akt1-/- osteoclasts have provided genetic evidence that Akt1
signaling promotes the differentiation and survival. The regulation
of differentiation might be dependent on the DNA binding of
NFkB, since previous knockdown studies of Akt1 and/or Akt2
showed inhibition of RANKL-induced NFkB p50 DNA-binding
activity via IkB kinase a [30].
By analogy with osteoblasts, the enhanced osteoclast survival by
Akt1 might be mediated by the FoxO3a/Bim axis, since Bim is
reported to be critical for osteoclast apoptosis [25]. However, this
is dependent on post-transcriptional regulation by ubiquitylation
and proteasomal degradation of Bim mediated by ERK pathway,
but not on transcriptional regulation as seen in the case of
osteoblast apoptosis. In addition, Bim in osteoclasts stimulates not
only the apoptosis, but also the bone resorptive activity. If Bim is
enhanced in Akt1-/- osteoclasts just as in the osteoblasts, the bone
resorption parameters like eroded surface are assumed to increase.
Hence, the mechanism by which Akt1 suppresses apoptosis in
osteoclasts is likely to be different from that in osteoblasts. The cell
autonomous mechanism of Akt1 in osteoclasts is the next task we
intend to pursue.
Akt1 as a mediator of bone anabolic signaling
Akt1 may mediate the osteoblastic bone formation by IGF-I and
insulin, since their effects on osteoblast survival and differentiation
were impaired in Akt1-/- osteoblasts (Fig 2C, 4A). Contrarily,
although BMP-2 induced phosphorylation of the entire Akt (Supp.
Fig S1A), the stimulated osteoblast differentiation was not affected
by the Akt1 deficiency (Fig 4A), suggesting the mediation of other
Akt isoforms or other pathways in the BMP-2 signaling. IGF-I is
known to function as a potent bone anabolic factor via autocrine/
paracrine and endocrine mechanisms [4], since skeletal and serum
IGF-I levels were positively correlated with bone density between
two inbred strains of mice [31]. Serum IGF-I levels of Akt1-/-
mice were comparable to that of WT in the age from 8 to
16 weeks (data not shown), suggesting the absence of reduced IGF-
I secretion or systemic compensation for impaired IGF-I signaling.
Hence, the decreased bone formation in vivo in Akt1-/- mice may
be at least in part due to the deficit of anabolic IGF-I signaling.
Considering that Akt1; Akt2 double-knockout mice and IGF-I
receptor knockout mice exhibit similar phenotypes [14,32], Akt
may be the main mediator of the IGF-I signaling. Bone anabolic
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action of other hormones like parathyroid hormone, growth
hormone, and thyroid hormone are reported to be mediated by
IGF-I signaling [33–36], and it is possible that the IGF-I/Akt1
pathway might be a common pathway for actions of these major
hormones in bone.
As presented herein, Akt1, a multifaceted kinase which mediates
various kinds of upstream signals to a diverse spectrum of substrates,
plays multiple roles in bone cells as well as other cell types reported.
Although it seems difficult to target this molecule directly in order to
yield novel therapeutics for bone disorders because of its ubiquitous
expression and diverse functions, further understanding of the
molecular network related to Akt1 will greatly help us to unravel the
complex mechanism modulating bone remodeling.
MATERIALS AND METHODS
Mice
The generation of Akt1-/- mice was described previously [11]. All
mice were maintained in the C57BL/6 background with
a standard diet. In each experiment, homozygous WT and
Akt1-/- mice that were littermates generated from the intercross
between heterozygous mice were compared. All experiments were
performed on 8-week-old male mice unless otherwise described,
according to the protocol approved by the Animal Care and Use
Committee of the University of Tokyo.
Radiological analyses
Plain radiographs were taken using a soft X-ray apparatus (CMB-
2, SOFTEX), and the BMD was measured by dual energy X-ray
absorptiometry (DXA) using a bone mineral analyzer (PIXImus
Densitometer, GE Medical Systems). CT scanning of the femurs
was performed using a composite X-ray analyzer (NX-CP-C80H-
IL, Nittetsu ELEX Co.), and reconstructed into a 3D feature by
the volume-rending method (VIP-Station, Teijin System Tech-
nology). pQCT scan was performed at the metaphysis 1.4 mm
above the distal growth plate and at the mid-shaft of femurs.
Histological analyses
For toluidine blue staining, samples were fixed with 70% ethanol,
embedded in methyl methacrylate, and sectioned in 6-mm slices.
Histomorphometric analyses were performed as described [37] in
the growth plate and secondary spongiosa (1.2 mm in length from
0.5 mm below the growth plate) of the proximal tibias, according
to the ASBMR nomenclature report [38]. For double labeling of
the mineralization front, mice were injected subcutaneously with
16 mg/kg body weight of calcein at 5 d and 1 d before sacrifice.
TRAP-positive cells were stained at pH 5.0 in the presence of L
(+)-tartaric acid using naphthol AS-MX phosphate (Sigma-
Aldrich) in N,N-dimethyl formamide as the substrate. Apoptotic
osteoblasts were detected by TUNEL method using an ApopTag
Peroxidase In Situ Apoptosis Detection Kit (Chemicon) on
paraffin-embedded sections of neonate mice. The percentage of
apoptotic cells was calculated by dividing the number of TUNEL-
positive cells by the number of counted cells. A total of at least 400
osteoblasts were counted in each section, and five to seven sections
per group were analyzed.
Osteoblastic cell cultures and assays
For osteoblast cultures, calvariae of neonatal mice were digested
by 0.1% collagenase and 0.2% dispase 5 times, and cells isolated
by the last 3 digestions were combined and cultured in a-minimal
essential medium (a-MEM) containing 10% FBS. Mouse osteo-
blastic MC3T3-E1 cells were cultured in the same way. Immature
mesenchymal C2C12 cells and C3H10T1/2 cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% FBS. Cell proliferation was determined using a BrdU
Labeling and Detection Kit III (Roche Diagnostics). After 24 h
culture in the presence and absence of insulin (100 nM), IGF-I
(10 nM), or FGF-2 (1 nM), the cells were labeled with BrdU for an
additional 4 h, and BrdU uptake was detected following the
manufacturer’s instructions. To determine the osteoblast apopto-
sis, the culture medium was changed to a serum-free one with and
without insulin or IGF-I, and total RNA or protein was collected
after designated times for subsequent assays. Cell survival was
determined by counting viable cell numbers using the Cell
Counting Kit-8 (Dojindo Molecular Technologies). Apoptotic
osteoblasts were further detected by TUNEL staining as described
above. Caspase-3 activity was measured via colorimetric detection
of the cleavage of caspase-specific substrates using an APOP-
CYTO Caspase-3 Colorimetric Assay Kit (MBL International
Co.). For ALP activity measurement, primary osteoblasts were
inoculated at a density of 56104 cells/well in a 24-multiwell plate
and cultured in a-MEM containing 10% FBS and 50 mg/ml
ascorbic acid. After 14 d of culture in the presence and absence of
insulin (100 nM), IGF-I (10 nM), or BMP-2 (30 ng/ml), cells were
sonicated in 10 mM Tris-HCl buffer (pH 8.0) containing 1 mM
MgCl2 and 0.5% Triton X-100. ALP activity in the lysate was
measured using an ALP Kit (Wako Pure Chemical). Protein
concentrations of cell lysates were measured with a Protein Assay
Kit II (BIO-RAD). For ALP staining, cells were fixed in 70%
ethanol and stained for 10 min with a solution containing 0.01%
naphthol AS-MX phosphate, 1% N,N-dimethyl formamide, and
0.06% fast blue BB (Sigma-Aldrich). For Alizarin red S and von
Kossa staining, osteoblasts were inoculated at a density of 16105
cells/well in a 12-multiwell plate in a-MEM containing 10% FBS
and 50 mg/ml ascorbic acid and 10 mM b-glycerophosphate
(Sigma-Aldrich). On day 21 after confluency, cultured cells were
fixed in 10% buffered formalin and stained for 10 min with 2%
Alizarin red S (pH 4.0) (Sigma-Aldrich). For von Kossa staining,
cells were fixed with 100% ethanol at room temperature for
15 min, stained with 5% silver nitrate solution under ultraviolet
light for 10 min, and incubated for 5 min with 5% sodium
thiosulfate solution.
Assays for osteoclastic cells
To study the role of Akt1 intrinsic to osteoclastic cells, we used
a coculture of osteoblasts and bone marrow cells and the M-CSF-
dependent BMM culture system as described previously [39].
Bone marrow cells were collected from long bones of 8-wk-old WT
or Akt1-/- littermates. TRAP-positive multinucleated osteoclasts
were generated by coculturing osteoblasts (16104 cells/well) and
bone marrow cells (56105 cells/well) derived from either WT or
Akt1-/- littermates in a 24-multiwell plate in a-MEM containing
10% FBS, 1,25(OH)2D3 (10 nM), and prostaglandin E2 (100 nM).
After 6 d, cells positively stained for TRAP containing more than
three nuclei were counted as osteoclasts. In the M-CSF-dependent
BMM culture system, bone marrow cells from WT or Akt1-/-
mice were seeded at a density of 36105 cells/well in a 24-multiwell
plate and cultured in a-MEM containing 10% FBS with M-CSF
(R&D Systems, 100 ng/ml) for 3 d. To generate mature
osteoclasts, adherent cells (BMM) were further cultured with M-
CSF (10 ng/ml) and soluble RANKL (Wako Pure Chemical,
100 ng/ml) for 3 additional days, then the number of TRAP-
positive osteoclasts was counted. To determine the survival, the
mature osteoclasts were deprived of M-CSF/soluble RANKL and
cultured for an additional 48 h. After 8, 24, and 48 h, the number
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of TRAP-positive and trypan blue-negative osteoclasts was
counted.
Real-time quantitative RT-PCR
Total RNA was extracted with ISOGEN (Wako Pure Chemical),
and an aliquot (1 mg) was reverse-transcribed using a PrimeScript
RT reagent Kit (Takara Bio) to make single-stranded cDNA. PCR
was performed on an ABI Prism 7000 Sequence Detection System
(Applied Biosystems) using QuantiTect SYBR Green PCR Master
Mix (QIAGEN) according to the manufacturer’s instructions. All
reactions were run in triplicate. After data collection, the mRNA
copy number of a specific gene in total RNA was calculated with
a standard curve generated with serially diluted plasmids contain-
ing PCR amplicon sequences, and normalized to the rodent total
RNA (Applied Biosystems) with mouse b-actin as an internal
control. Standard plasmids were synthesized with a TOPO TA
Cloning Kit (Invitrogen), according to the manufacturer’s in-
struction. Primer sequences are stated in the Supporting Protocol
S1 online.
Western blot analyses
Cells were washed twice with ice-cold PBS, and proteins were
extracted with M-PER (Pierce Chemical) or NE-PER (Pierce
Chemical), according to the manufacturer’s instructions. To detect
the phosphorylation of FoxO3a, the lysates were treated with
lambda protein phosphatase (New England Bio Labs). For
Western blot analysis, lysates were fractionated by SDS-PAGE
with 7.5–15% Tris-Glycin gradient gel or 15% Tris-Glycin gel,
and transferred onto nitrocellulose membranes (BIO-RAD). After
blocking with 6% milk/TBS-T, membranes were incubated with
primary antibodies to pan-Akt, phospho-Akt, Akt1, Akt2, FoxO1,
cleaved caspase-3, Bax, Bcl-2 (Cell Signaling Technology),
FoxO3a (Upstate), Bim (BD Parmingen), Bcl-xL (Santa Cruz
Biotechnology), and b-actin (Sigma-Aldrich), followed with HRP-
conjugated goat anti-mouse IgG and goat anti-rabbit IgG
(Promega). Immunoreactive bands were visualized with ECL Plus
(Amersham), according to the manufacturer’s instructions.
Luciferase assays
MC3T3-E1 cells were plated onto 24-well plates, then sub-
sequently transfected in triplicate with 0.1 mg of the reporter
plasmid, 0.2 mg of effector plasmids, and 8 ng of pRL-TK vector
(Promega) for internal control, by using FuGENE6 (Roche
Diagnostics). The amount of total DNA in each well was adjusted
to be equal. Details are described in Supporting Protocol S1
online. The luciferase assay was performed 48 h after transfection
with a dual-luciferase reporter assay system and GloMaxTM 96
Microplate Luminometer (Promega). Firefly output was normal-
ized to Renilla output to control for transfection efficiency.
ChIP assay
ChIP assay was performed with a ChIP Assay Kit (Upstate),
according to the manufacturer’s instructions. PCR was performed
to amplify the promoter region (2471/267) of osteocalcin gene
containing the OSE2 site which Runx2 is reported to bind [40].
Primer sequences are given in Supporting Protocol S1 online.
Statistical analyses
Means of groups were compared by ANOVA and significance of
differences was determined by post-hoc testing with Bonferroni’s
method.
SUPPORTING INFORMATION
Figure S1 Phosphorylation and expression pattern of Akt isoforms
in bone cells. (A) Time course of phosphorylated total Akt (P-Akt)
and total Akt (Akt) levels determined by Western blotting in cultured
mouse calvarial osteoblasts (OB) after stimulation with IGF-I or
BMP-2, and in cultured bone marrow macrophages (BMM) and
mature osteoclasts (OC) after stimulation with M-CSF. (B)
Expressions of each Akt isoform in the cells above determined by
quantitative real-time RT-PCR analysis using the same amount of
template cDNA. Data are expressed as means (bars)6SEM (error
bars) of the relative amount of mRNA as compared to that of Akt1.
Found at: doi:10.1371/journal.pone.0001058.s001 (0.49 MB TIF)
Figure S2 Akt1-/- mice showed growth retardation. (A) Body
weight and naso-anal length of WT (+/+) and Akt1-/- littermates.
Data are expressed as means (symbols)6SEM (error bars) for 4–10
mice/group. *P,0.05 vs. WT. (B) Plain X-ray images of the whole
body of representative male littermates at 8 weeks of age. Bar, 1 cm.
Found at: doi:10.1371/journal.pone.0001058.s002 (1.47 MB TIF)
Figure S3 FoxO3a translocated into nucleus after serum
deprivation. Time course of subcellular localization of GFP-
tagged FoxO3a after serum deprivation in MC3T3-E1 cells. Bar,
20 mm.
Found at: doi:10.1371/journal.pone.0001058.s003 (2.16 MB TIF)
Figure S4 Effects of Actinomycin D, insulin, and IGF-I on Bim
expression after serum deprivation. (A) Time course of Bim
mRNA level determined by real-time RT-PCR after serum
deprivation in cultured calvarial osteoblasts with and without
Actinomycin D (1 mM). Data are normalized to those of b-actin
and are expressed as means (symbols)6SEM (error bars) of the
relative amount compared to time 0. (B) Time course of Bim
protein level determined by Western blotting after serum
deprivation in cultured calvarial osteoblasts with and without
Actinomycin D (1 mM). (C) Time course of Bim mRNA level
determined by real-time RT-PCR after serum deprivation in
cultured calvarial osteoblasts with and without insulin (100 nM),
IGF-I (10 nM), or FBS (10%). Data are normalized to those of b-
actin and are expressed as means (symbols)6SEM (error bars) of
the relative amount compared to time 0.
Found at: doi:10.1371/journal.pone.0001058.s004 (0.38 MB TIF)
Figure S5 Akt1 did not affect osteoblastic differentiation of
immature mesenchymal cell lines. ALP staining of cultured C2C12
cells and C3H10T1/2 cells that were adenovirally transfected with
GFP, Akt1CA, or Runx2.
Found at: doi:10.1371/journal.pone.0001058.s005 (1.52 MB TIF)
Protocol S1
Found at: doi:10.1371/journal.pone.0001058.s006 (0.10 MB
DOC)
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